Candidate Compounds Covid19

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
(007)
K
 
(46 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
{{pnc}}
+
{{gohome}}
 +
{{ft|P}}
 +
  '''CHERRYPICKING STUDIES IS NOT SCIENCE
 +
{{qt|Reviews on covid drug development}}
  
current items will be put into the subsections.
 
  
*[[reviews on covid drug development]]
+
*'''[[scouting ideas]]'''
*[[scouting ideas]]
+
  
*[[Patients on biologicals]]
+
*'''[[PHA Biologicals]]'''
*[[HMGB1, RAGE]]
+
*[[pre-Interleukin 6]]
+
*[[post-Interleukin 6]]
+
*[[pre-TNFalpha]]
+
*[[post-TNFalpha]]
+
*[[pre-Interleukin 17]]
+
*[[post-Interleukin 17]]
+
*[[pre-Interleukin 1]]
+
*[[post-Interleukin 1]]
+
*[[Inflammasome]] ''colchicine''
+
*[[other anti-inflammatory]]
+
*[[NK-kappaB]]
+
*[[STAT 3]]
+
*[[JAK Janus Kinase]]
+
*[[Corticosteroids]]
+
*[[Cytokine absorbers]]
+
*[[Target Complement system]]
+
*[[Target Extracellular traps]]
+
*[[Anticoagulant in covid19]]
+
*[[Antioxidants]]
+
*[[Stem cells]]
+
*[[MDSC cells]]
+
*[[Interferons]]
+
  
 +
*'''[[PHA conventional pharmacology]]'''
  
*[[other single compounds]]
+
*'''[[PHA retargeted compounds]]'''
*[[Retargeted single compounds]]
+
*[[Hydroxychloroquine]]
+
*
+
*[[Target ACE2, Spike protein]]
+
*[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
+
*[[other antiviral compounds]]
+
*[[AV Remdesivir]]
+
*[[AV Lopinavir]]
+
*[[AV Ivermectin]]
+
  
 +
*'''[[PHA antivirals by mechanism]]'''
  
 +
*'''[[PHA pharmacophore by screened target]]'''
  
 +
*'''[[PHA ImmunoNutrients]]
  
*[[Vitamin D]]
+
*'''[[PHA compl altern natural]]'''
*[[Anorganic nutrients Magnesium]]
+
*[[Anorganic nutrients Selenium]]
+
*[[Anorganic nutrients Zinc]]
+
*[[Nutrition, general]]
+
*[[Exercise, Vibration]]
+
  
 +
*'''[[PHA within indications compounds]]'''
  
*[[Traditional Chinese Medicine]]
+
*'''[[PHA Serum products]]'''
*[[Natural compounds]]
+
  
*[[Statins]]
+
*'''[[PHA Vaccination]]'''
*[[Antidiabetic compounds, any]]
+
*[[RSP - On RAS drugs]]
+
  
*[[Reconvalescent blood products, Passive vaccine]]
+
PHA related options:
*[[Plasmapheresis]]
+
  
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
 
 
*[[Radiation therapy]]
 
*[[Radiation therapy]]
 
*[[Phototherapy]]
 
*[[Phototherapy]]
*[[Active vaccine]]  
+
*[[Electric fields]]
 +
*[[Treatment other concepts]]
  
===007===
 
  
 +
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
 +
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
 +
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
 +
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
 +
based on e.g.
  
{{tp|p=32496248|t=2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.|pdf=|usr=007}}
+
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
{{tp|p=32496246|t=2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.|pdf=|usr=007}}
+
  
 +
=======================================================================================
  
{{tp|p=32468742|t=2020. Reply: Vitamin C as a Possible Therapy for COVID-19.|pdf=|usr=007}}
+
COVID19 is now a CURABLE disease !!!
{{tp|p=32410417|t=2020. Vitamin C as a Possible Therapy for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32476308|t=2020. Empirical Treatment and Prevention of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32466136|t=2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.|pdf=|usr=007}}
+
{{tp|p=32455961|t=2020. Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel.|pdf=|usr=007}}
+
{{tp|p=32486229|t=2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.|pdf=|usr=007}}
+
{{tp|p=32481690|t=2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.|pdf=|usr=007}}
+
{{tp|p=32471278|t=2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.|pdf=|usr=007}}
+
{{tp|p=32471272|t=2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?|pdf=|usr=007}}
+
  
 
+
=======================================================================================
{{tp|p=32443911|t=2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=007}}
+
{{tp|p=32429099|t=2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
+
{{tp|p=32392184|t=2020. Clinical trials for COVID-19 should include sex as a variable.|pdf=|usr=007}}
+
{{tp|p=32456123|t=2020. Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.|pdf=|usr=007}}
+
 
+
{{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
+
 
+
{{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=007}}
+
 
+
{{tp|p=32475851|t=2020. COVID-19: Stay Cool toward Corticosteroids.|pdf=|usr=007}}
+
{{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
+
{{tp|p=32293020|t=2020. Palliativ farmakologisk behandling vid svar covid-19.|pdf=|usr=007}}
+
{{tp|p=32444382|t=2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.|pdf=|usr=007}}
+
{{tp|p=32442946|t=2020. inverted question markBCG versus COVID-19?|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32162896|t=2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.|pdf=|usr=007}}
+
{{tp|p=32407051|t=2020. Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32455942|t=2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.|pdf=|usr=007}}
+
 
+
{{tp|p=32408547|t=2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).|pdf=|usr=007}}
+
{{tp|p=32486364|t=2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.|pdf=|usr=007}}
+
 
+
{{tp|p=32397511|t=2020. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32486488|t=2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.|pdf=|usr=007}}
+
{{tp|p=32471251|t=2020. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis.|pdf=|usr=007}}
+
{{tp|p=32438620|t=2020. COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation.|pdf=|usr=007}}
+
{{tp|p=32492809|t=2020. Vitamin D Supplementation in Influenza and COVID-19 Infections Comment on: "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths" Nutrients 2020, 12(4), 988.|pdf=|usr=007}}
+
{{tp|p=32492787|t=2020. Reply: "Vitamin D Supplementation in Influenza and COVID-19 Infections. Comment on: Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths Nutrients 2020, 12(4), 988".|pdf=|usr=007}}
+
{{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
+
{{tp|p=32471171|t=2020. Excess Ascorbate is a Chemical Stress Agent against Proteins and Cells.|pdf=|usr=007}}
+
 
+
{{tp|p=32423024|t=2020. The Rationale for Potential Pharmacotherapy of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32434254|t=2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.|pdf=|usr=007}}
+
{{tp|p=32470046|t=2020. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.|pdf=|usr=007}}
+
 
+
{{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
+
{{tp|p=32491112|t=2020. Does Vitamin D play a role in the management of Covid-19 in Brazil?|pdf=|usr=007}}
+
{{tp|p=32381590|t=2020. Ethics of controlled human infection to address COVID-19.|pdf=|usr=007}}
+
{{tp|p=32472653|t=2020. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.|pdf=|usr=007}}
+
{{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
+
 
+
{{tp|p=32447783|t=2020. Convalescent plasma for COVID-19: Back to the future.|pdf=|usr=007}}
+
{{tp|p=32449169|t=2020. How did we rapidly implement a convalescent plasma program?|pdf=|usr=007}}
+
{{tp|p=32449171|t=2020. COVID-19: are neutralizing antibodies neutralizing enough?|pdf=|usr=007}}
+
{{tp|p=32428966|t=2020. COVID-19 convalescent plasma donor recruitment: beware the Faustian bargains.|pdf=|usr=007}}
+
{{tp|p=32395792|t=2020. COVID-19: Main therapeutic options.|pdf=|usr=007}}
+
{{tp|p=32507409|t=2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32486283|t=2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.|pdf=|usr=007}}
+
{{tp|p=32397643|t=2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.|pdf=|usr=007}}
+
{{tp|p=32464700|t=2020. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.|pdf=|usr=007}}
+
{{tp|p=32485102|t=2020. Current Perspective of Antiviral Strategies against COVID-19.|pdf=|usr=007}}
+
{{tp|p=32369098|t=2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=007}}
+
{{tp|p=32398379|t=2020. Convalescent plasma for patients with COVID-19.|pdf=|usr=007}}
+
{{tp|p=32398378|t=2020. Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.|pdf=|usr=007}}
+
{{tp|p=32398377|t=2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.|pdf=|usr=007}}
+
{{tp|p=32438839|t=2020. Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?|pdf=|usr=007}}
+
{{tp|p=32462848|t=2020. Interleukine-1 et blocage du COVID-19.|pdf=|usr=007}}
+
{{tp|p=32495979|t=2020. Emergence of novel coronavirus and progress toward treatment and vaccine.|pdf=|usr=007}}
+
{{tp|p=32512588|t=2020. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32453251|t=2020. Extracorporeal Hemoadsorption: An Option for COVID-19 Associated Cytokine Storm Syndrome.|pdf=|usr=007}}
+
{{tp|p=32496422|t=2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.|pdf=|usr=007}}
+
{{tp|p=32500793|t=2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32380908|t=2020. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.|pdf=|usr=007}}
+
{{tp|p=32433189|t=2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.|pdf=|usr=007}}
+
 
+
{{tp|p=32473596|t=2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.|pdf=|usr=007}}
+
{{tp|p=32491199|t=2020. Feasibility of a Pilot Program for COVID-19 Convalescent Plasma Collection in Wuhan, China.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32391659|t=2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].|pdf=|usr=007}}
+
 
+
{{tp|p=32489024|t=2020. [Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors].|pdf=|usr=007}}
+
{{tp|p=32450629|t=2020. [Application of convalescent plasma therapy on novel coronavirus infection].|pdf=|usr=007}}
+
{{tp|p=32034899|t=2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32057209|t=2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].|pdf=|usr=007}}
+
{{tp|p=32397700|t=2020. [Analysis of application of herd immunity as a control strategy for COVID-19].|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32473600|t=2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=007}}
+
{{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=007}}
+
{{tp|p=32490731|t=2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.|pdf=|usr=007}}
+
 
+
{{tp|p=32403995|t=2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.|pdf=|usr=007}}
+
{{tp|p=32499303|t=2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.|pdf=|usr=007}}
+
{{tp|p=32496239|t=2020. Potential pharmacological agents for COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32496237|t=2020. AYUSH for COVID-19: Science or Superstition?|pdf=|usr=007}}
+
{{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=007}}
+
{{tp|p=32392562|t=2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32510105|t=2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.|pdf=|usr=007}}
+
 
+
{{tp|p=32462719|t=2020. Nutrition Therapy in Critically Ill Patients with Coronavirus Disease (COVID-19).|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32505909|t=2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.|pdf=|usr=007}}
+
{{tp|p=32512490|t=2020. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32492560|t=2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?|pdf=|usr=007}}
+
{{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
+
{{tp|p=32512493|t=2020. The effects of allium sativum on immunity within the scope of COVID-19 infection.|pdf=|usr=007}}
+
{{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=007}}
+
{{tp|p=32492996|t=2020. Management of nutritional consultations in local clinics during SARS-CoV-2 pandemic.|pdf=|usr=007}}
+
{{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
+
{{tp|p=32506067|t=2020. Covid-19 and Exercise-Induced Immunomodulation.|pdf=|usr=007}}
+
 
+
{{tp|p=32468635|t=2020. Food as medicine: a possible preventive measure against coronavirus disease (COVID-19).|pdf=|usr=007}}
+
{{tp|p=32442323|t=2020. Curcumin as a potential treatment for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32430996|t=2020. Potential effects of curcumin in the treatment of COVID-19 infection.|pdf=|usr=007}}
+
{{tp|p=32424845|t=2020. Artemisia annua: Trials are needed for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32492211|t=2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.|pdf=|usr=007}}
+
 
+
{{tp|p=32492205|t=2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.|pdf=|usr=007}}
+
 
+
{{tp|p=32421836|t=2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.|pdf=|usr=007}}
+
{{tp|p=32506862|t=2020. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients.|pdf=|usr=007}}
+
{{tp|p=32427774|t=2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.|pdf=|usr=007}}
+
{{tp|p=32427277|t=2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.|pdf=|usr=007}}
+
{{tp|p=32495940|t=2020. Probiotics and COVID-19: is there any link?|pdf=|usr=007}}
+
{{tp|p=32504751|t=2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.|pdf=|usr=007}}
+
{{tp|p=32505910|t=2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.|pdf=|usr=007}}
+
{{tp|p=32502901|t=2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.|pdf=|usr=007}}
+
 
+
{{tp|p=32505070|t=2020. Nebulized Lidocaine in COVID-19, An Hypothesis.|pdf=|usr=007}}
+
 
+
{{tp|p=32369285|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369284|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369283|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369282|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369281|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=007}}
+
{{tp|p=32325475|t=2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.|pdf=|usr=007}}
+
 
+
{{tp|p=32393915|t=2020. Biggest COVID-19 trial tests repurposed drugs first.|pdf=|usr=007}}
+
{{tp|p=32417850|t=2020. Drug researchers pursue new lines of attack against COVID-19.|pdf=|usr=007}}
+
{{tp|p=32415300|t=2020. Biotech companies prepare for COVID-19 downturn.|pdf=|usr=007}}
+
{{tp|p=32415251|t=2020. 15 drugs being tested to treat COVID-19 and how they would work.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32422645|t=2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.|pdf=|usr=007}}
+
{{tp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.|pdf=|usr=007}}
+
{{tp|p=32415276|t=2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.|pdf=|usr=007}}
+
{{tp|p=32409766|t=2020. Dozens of coronavirus drugs are in development - what happens next?|pdf=|usr=007}}
+
{{tp|p=32405023|t=2020. Coronavirus drugs trials must get bigger and more collaborative.|pdf=|usr=007}}
+
 
+
{{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=007}}
+
{{tp|p=32504019|t=2020. The coronavirus outbreak could make it quicker and easier to trial drugs.|pdf=|usr=007}}
+
{{tp|p=32424192|t=2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.|pdf=|usr=007}}
+
 
+
{{tp|p=32299148|t=2020. Considerations for Obesity, Vitamin D, and Physical Activity Amid the COVID-19 Pandemic.|pdf=|usr=007}}
+
 
+
{{tp|p=32324361|t=2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]|pdf=|usr=007}}
+
 
+
{{tp|p=32398330|t=2020. A Call for Pediatric COVID-19 Clinical Trials.|pdf=|usr=007}}
+
{{tp|p=32423342|t=2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?|pdf=|usr=007}}
+
{{tp|p=32393419|t=2020. Recent advances of therapeutic targets and potential drugs of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32476189|t=2020. SARS-CoV-2 pandemic and Vitamin D deficiency-A double trouble.|pdf=|usr=007}}
+
{{tp|p=32472655|t=2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.|pdf=|usr=007}}
+
{{tp|p=32501634|t=2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?|pdf=|usr=007}}
+
{{tp|p=32488956|t=2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32439730|t=2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?|pdf=|usr=007}}
+
 
+
{{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
+
{{tp|p=32472681|t=2020. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.|pdf=|usr=007}}
+
{{tp|p=32385052|t=2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32381697|t=2020. The race is on for antibodies that stop the new coronavirus.|pdf=|usr=007}}
+
{{tp|p=32381692|t=2020. Combination prevention for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32393526|t=2020. A strategic approach to COVID-19 vaccine R&D.|pdf=|usr=007}}
+
{{tp|p=32385100|t=2020. Rapid COVID-19 vaccine development.|pdf=|usr=007}}
+
{{tp|p=32461212|t=2020. Reducing transmission of SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32385101|t=2020. Rapid repurposing of drugs for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32327575|t=2020. NIH organizes hunt for drugs.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32409433|t=2020. Antivirals for COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32456767|t=2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?|pdf=|usr=007}}
+
 
+
{{tp|p=32490931|t=2020. 17beta-Estradiol, a potential ally to alleviate SARS-CoV-2 infection.|pdf=|usr=007}}
+
{{tp|p=32444482|t=2020. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.|pdf=|usr=007}}
+
{{tp|p=32409522|t=2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.|pdf=|usr=007}}
+
{{tp|p=32420637|t=2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.|pdf=|usr=007}}
+
{{tp|p=32294756|t=2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.|pdf=|usr=007}}
+
 
+
{{tp|p=32438473|t=2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.|pdf=|usr=007}}
+
{{tp|p=32496938|t=2020. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.|pdf=|usr=007}}
+
{{tp|p=32512271|t=2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.|pdf=|usr=007}}
+
{{tp|p=32512383|t=2020. Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy.|pdf=|usr=007}}
+
 
+
{{tp|p=32448098|t=2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.|pdf=|usr=007}}
+
 
+
{{tp|p=32448085|t=2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.|pdf=|usr=007}}
+
 
+
{{tp|p=32431217|t=2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32469418|t=2020. Evaluation of potential therapeutic options for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32445400|t=2020. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?|pdf=|usr=007}}
+
{{tp|p=32441805|t=2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.|pdf=|usr=007}}
+
{{tp|p=32437001|t=2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".|pdf=|usr=007}}
+
 
+
{{tp|p=32472779|t=2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?|pdf=|usr=007}}
+
{{tp|p=32508069|t=2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.|pdf=|usr=007}}
+
{{tp|p=32470199|t=2020. Metformin use amid coronavirus disease 2019 pandemic.|pdf=|usr=007}}
+
{{tp|p=32470160|t=2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.|pdf=|usr=007}}
+
{{tp|p=32458502|t=2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32458475|t=2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.|pdf=|usr=007}}
+
 
+
{{tp|p=32458425|t=2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.|pdf=|usr=007}}
+
{{tp|p=32441786|t=2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.|pdf=|usr=007}}
+
{{tp|p=32437024|t=2020. Convalescent plasma therapy: A passive therapy for an aggressive COVID-19.|pdf=|usr=007}}
+
{{tp|p=32437019|t=2020. Baricitinib: A chance to treat COVID-19?|pdf=|usr=007}}
+
{{tp|p=32437014|t=2020. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
+
{{tp|p=32492084|t=2020. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.|pdf=|usr=007}}
+
{{tp|p=32428941|t=2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32449669|t=2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.|pdf=|usr=007}}
+
 
+
{{tp|p=32495917|t=2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
{{tp|p=32427004|t=2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?|pdf=|usr=007}}
+
{{tp|p=32452701|t=2020. An up-to-date overview of computational polypharmacology in modern drug discovery.|pdf=|usr=007}}
+
 
+
{{tp|p=32447996|t=2020. Treatments in the COVID-19 pandemic: an update on clinical trials.|pdf=|usr=007}}
+
{{tp|p=32475183|t=2020. Does lopinavir measure up in the treatment of COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32282262|t=2020. Treatment considerations for coronavirus (COVID-19).|pdf=|usr=007}}
+
{{tp|p=32469280|t=2020. COVID-19: Gene Transfer to the Rescue?|pdf=|usr=007}}
+
{{tp|p=32423245|t=2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.|pdf=|usr=007}}
+
{{tp|p=32212981|t=2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.|pdf=|usr=007}}
+
{{tp|p=32501133|t=2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?|pdf=|usr=007}}
+
{{tp|p=32503817|t=2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.|pdf=|usr=007}}
+
{{tp|p=32503816|t=2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.|pdf=|usr=007}}
+
 
+
{{tp|p=32503814|t=2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32449676|t=2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.|pdf=|usr=007}}
+
{{tp|p=32468014|t=2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).|pdf=|usr=007}}
+
{{tp|p=32401694|t=2020. Flying by the seat of our pants: is low dose radiation therapy for COVID-19 an option?|pdf=|usr=007}}
+
 
+
{{tp|p=32468508|t=2020. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.|pdf=|usr=007}}
+
{{tp|p=32310670|t=2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32443151|t=2020. Lopinavir pharmacokinetics in COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32462858|t=2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.|pdf=|usr=007}}
+
{{tp|p=32469279|t=2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.|pdf=|usr=007}}
+
 
+
{{tp|p=32462988|t=2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).|pdf=|usr=007}}
+
 
+
{{tp|p=32475223|t=2020. Antiviral effects of probiotic metabolites on COVID-19.|pdf=|usr=007}}
+
{{tp|p=32462970|t=2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32462996|t=2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.|pdf=|usr=007}}
+
 
+
{{tp|p=32476574|t=2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.|pdf=|usr=007}}
+
{{tp|p=32485061|t=2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.|pdf=|usr=007}}
+
{{tp|p=32487869|t=2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?|pdf=|usr=007}}
+
{{tp|p=32433345|t=2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32511763|t=2020. Colchicine and COVID-19.|pdf=|usr=007}}
+
{{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}}
+
{{tp|p=32504739|t=2020. Interleukin-17: A potential therapeutic target in COVID-19.|pdf=|usr=007}}
+
{{tp|p=32473010|t=2020. TPE-nAbs combination therapy for severe COVID-19.|pdf=|usr=007}}
+
{{tp|p=32220033|t=2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).|pdf=|usr=007}}
+
 
+
{{tp|p=32511912|t=2020. COVID-19: Drug targets and potential treatments.|pdf=|usr=007}}
+
{{tp|p=32469301|t=2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.|pdf=|usr=007}}
+
 
+
{{tp|p=32472703|t=2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.|pdf=|usr=007}}
+
{{tp|p=32427773|t=2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.|pdf=|usr=007}}
+
{{tp|p=32364561|t=2020. Randomized Clinical Trials and COVID-19: Managing Expectations.|pdf=|usr=007}}
+
{{tp|p=32463427|t=2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.|pdf=|usr=007}}
+
{{tp|p=32453363|t=2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.|pdf=|usr=007}}
+
{{tp|p=32492105|t=2020. A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals.|pdf=|usr=007}}
+
 
+
{{tp|p=32506195|t=2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32463794|t=2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.|pdf=|usr=007}}
+
{{tp|p=32432810|t=2020. Letter: does vitamin D have a potential role against COVID-19?|pdf=|usr=007}}
+
{{tp|p=32434272|t=2020. COVID-19Clinical trials: quality matters more than quantity.|pdf=|usr=007}}
+
{{tp|p=32384798|t=2020. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19.|pdf=|usr=007}}
+
{{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
+
{{tp|p=32505821|t=2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.|pdf=|usr=007}}
+
 
+
{{tp|p=32455629|t=2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.|pdf=|usr=007}}
+
 
+
{{tp|p=32398343|t=2020. Should azithromycin be used to treat COVID-19? A rapid review.|pdf=|usr=007}}
+
{{tp|p=32464624|t=2020. Cytokine Blood Filtration Responses in COVID-19.|pdf=|usr=007}}
+
{{tp|p=32454500|t=2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.|pdf=|usr=007}}
+
{{tp|p=32453693|t=2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".|pdf=|usr=007}}
+
{{tp|p=32453692|t=2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.|pdf=|usr=007}}
+
{{tp|p=32453687|t=2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32267762|t=2020. Research towards treating COVID-19.|pdf=|usr=007}}
+
{{tp|p=32453903|t=2020. Efficacy of therapeutic plasma exchange in severe COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32438450|t=2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.|pdf=|usr=007}}
+
{{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}}
+
{{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
+
{{tp|p=32441783|t=2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).|pdf=|usr=007}}
+
{{tp|p=32441764|t=2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?|pdf=|usr=007}}
+
{{tp|p=32424836|t=2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.|pdf=|usr=007}}
+
{{tp|p=32449802|t=2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?|pdf=|usr=007}}
+
{{tp|p=32512007|t=2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.|pdf=|usr=007}}
+
{{tp|p=32445484|t=2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.|pdf=|usr=007}}
+
{{tp|p=32438446|t=2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.|pdf=|usr=007}}
+
{{tp|p=32508009|t=2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.|pdf=|usr=007}}
+
{{tp|p=32441462|t=2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32511867|t=2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.|pdf=|usr=007}}
+
{{tp|p=32418327|t=2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.|pdf=|usr=007}}
+
{{ttp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=007}}
+
 
+
{{tp|p=32420947|t=2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).|pdf=|usr=007}}
+
{{tp|p=32420936|t=2020. Treatments for COVID-19: emerging drugs against the coronavirus.|pdf=|usr=007}}
+
{{tp|p=32425152|t=2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.|pdf=|usr=007}}
+
{{tp|p=32506621|t=2020. Drugs being investigated for children with COVID-19.|pdf=|usr=007}}
+
{{tp|p=32468505|t=2020. Association between low vitamin D and COVID-19: don't forget the vitamin D binding protein.|pdf=|usr=007}}
+
{{tp|p=32423954|t=2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.|pdf=|usr=007}}
+
 
+
{{tp|p=32493028|t=2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.|pdf=|usr=007}}
+
{{tp|p=32362105|t=2020. What information can I share with my patients about nutrition during COVID-19?|pdf=|usr=007}}
+
{{tp|p=32510142|t=2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32407491|t=2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.|pdf=|usr=007}}
+
 
+
{{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=007}}
+
{{tp|p=32345591|t=2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.|pdf=|usr=007}}
+
{{tp|p=32303505|t=2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.|pdf=|usr=007}}
+
{{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=007}}
+
 
+
{{tp|p=32480418|t=2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.|pdf=|usr=007}}
+
 
+
{{tp|p=32498751|t=2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.|pdf=|usr=007}}
+
 
+
{{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=007}}
+
{{tp|p=32412788|t=2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32503806|t=2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.|pdf=|usr=007}}
+
{{tp|p=32474583|t=2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.|pdf=|usr=007}}
+
{{tp|p=32459003|t=2020. A role for retinoids in the treatment of COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32459832|t=2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.|pdf=|usr=007}}
+
{{tp|p=32442287|t=2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|pdf=|usr=007}}
+
 
+
{{tp|p=32427279|t=2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.|pdf=|usr=007}}
+
{{tp|p=32503801|t=2020. Does vitamin D deficiency increase the severity of COVID-19?|pdf=|usr=007}}
+
{{tp|p=32341077|t=2020. Nutritional status and COVID-19: an opportunity for lasting change?|pdf=|usr=007}}
+
 
+
{{tp|p=32498131|t=2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.|pdf=|usr=007}}
+
 
+
{{tp|p=32350861|t=2020. COVID-19: A Defining Moment for Clinical Pharmacology?|pdf=|usr=007}}
+
{{tp|p=32442315|t=2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32420691|t=2020. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.|pdf=|usr=007}}
+
{{tp|p=32212378|t=2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.|pdf=|usr=007}}
+
{{tp|p=32406927|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.|pdf=|usr=007}}
+
{{tp|p=32284037|t=2020. Perspective on the COVID-19 Coronavirus Outbreak.|pdf=|usr=007}}
+
{{tp|p=32174284|t=2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.|pdf=|usr=007}}
+
{{tp|p=32400323|t=2020. In vitro data of current therapies for SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32427000|t=2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32487877|t=2020. Editorial: Challenges and Insights amidst the Covid-19 pandemic: Nutrition, the immune system and disease risk.|pdf=|usr=007}}
+
{{tp|p=32487876|t=2020. Nutrition in times of Covid-19, how to trust the deluge of scientific information.|pdf=|usr=007}}
+
{{tp|p=32479246|t=2020. Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.|pdf=|usr=007}}
+
{{tp|p=32416679|t=2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.|pdf=|usr=007}}
+
{{tp|p=32394841|t=2020. COVID-19: An Update on Clinical Trials.|pdf=|usr=007}}
+
{{tp|p=32282303|t=2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.|pdf=|usr=007}}
+
{{tp|p=32475041|t=2020. Potential role of Anti-IL-17 in COVID-19 treatment.|pdf=|usr=007}}
+
{{tp|p=32473070|t=2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?|pdf=|usr=007}}
+
{{tp|p=32510814|t=2020. Omalizumab and COVID19 Treatment: Could It Help?|pdf=|usr=007}}
+
{{tp|p=32510734|t=2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.|pdf=|usr=007}}
+
{{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=007}}
+
{{tp|p=32419517|t=2020. Emerging therapies for COVID-19 pneumonia.|pdf=|usr=007}}
+
{{tp|p=32429703|t=2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.|pdf=|usr=007}}
+
{{tp|p=32419524|t=2020. Old and re-purposed drugs for the treatment of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32223349|t=2020. How could artificial intelligence aid in the fight against coronavirus?|pdf=|usr=007}}
+
{{tp|p=32490453|t=2020. Luminescent silicon nanostructures and COVID-19.|pdf=|usr=007}}
+
{{tp|p=32500928|t=2020. COVID-19 breakthroughs: separating fact from fiction.|pdf=|usr=007}}
+
 
+
{{tp|p=32505474|t=2020. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy.|pdf=|usr=007}}
+
{{tp|p=32419212|t=2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?|pdf=|usr=007}}
+
{{tp|p=32505362|t=2020. Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32401673|t=2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.|pdf=|usr=007}}
+
{{tp|p=32420751|t=2020. Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.|pdf=|usr=007}}
+
{{tp|p=32428965|t=2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.|pdf=|usr=007}}
+
{{tp|p=32479158|t=2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?|pdf=|usr=007}}
+
{{tp|p=32464083|t=2020. P-selectin blockade in COVID-19-related ARDS.|pdf=|usr=007}}
+
{{tp|p=32437628|t=2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32446312|t=2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.|pdf=|usr=007}}
+
{{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=007}}
+
{{tp|p=32503853|t=2020. COVID-19 infection in a patient with FMF: does colchicine have a protective effect?|pdf=|usr=007}}
+
{{tp|p=32340978|t=2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.|pdf=|usr=007}}
+
-rest-
+
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
+
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
+
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
+
{{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
+
{{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
+
{{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
+
{{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
+
{{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
+
{{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
+
{{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
+
{{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
+
{{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
+
{{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
+

Aktuelle Version vom 21. September 2021, 06:15 Uhr

homepage
hottest actual papers
 P further streaming-in related content is here
 CHERRYPICKING STUDIES IS NOT SCIENCE
Reviews on covid drug development


PHA related options:


A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis